PURPOSE: Practice guidelines recommend that patients who receive neoadjuvant chemotherapy and radiation for locally advanced rectal cancer complete postoperative adjuvant systemic chemotherapy, irrespective of tumor downstaging. PATIENTS AND METHODS: The National Comprehensive Cancer Network (NCCN) Colorectal Cancer Database tracks longitudinal care for patients treated at eight specialty cancer centers across the United States and was used to evaluate how frequently patients with rectal cancer who were treated with neoadjuvant chemotherapy also received postoperative systemic chemotherapy. Patient and tumor characteristics were examined in a multivariable logistic regression model. RESULTS: Between September 2005 and December 2010, 2,073 patients with stage II/III rectal cancer were enrolled in the database. Of these, 1,193 patients receiving neoadjuvant chemoradiotherapy were in the analysis, including 203 patients not receiving any adjuvant chemotherapy. For those seen by a medical oncologist, the most frequent reason chemotherapy was not recommended was comorbid illness (25 of 50, 50%); the most frequent reason chemotherapy was not received even though it was recommended or discussed was patient refusal (54 of 74, 73%). After controlling for NCCN Cancer Center and clinical TNM stage in a multivariable logistic model, factors significantly associated with not receiving adjuvant chemotherapy were age, Eastern Cooperative Oncology Group performance status ≥ 1, on Medicaid or indigent compared with private insurance, complete pathologic response, presence of re-operation/wound infection, and no closure of ileostomy/colostomy. CONCLUSION: Even at specialty cancer centers, a sizeable minority of patients with rectal cancer treated with curative-intent neoadjuvant chemoradiotherapy do not complete postoperative chemotherapy. Strategies to facilitate the ability to complete this third and final component of curative intent treatment are necessary.
PURPOSE: Practice guidelines recommend that patients who receive neoadjuvant chemotherapy and radiation for locally advanced rectal cancer complete postoperative adjuvant systemic chemotherapy, irrespective of tumor downstaging. PATIENTS AND METHODS: The National Comprehensive Cancer Network (NCCN) Colorectal Cancer Database tracks longitudinal care for patients treated at eight specialty cancer centers across the United States and was used to evaluate how frequently patients with rectal cancer who were treated with neoadjuvant chemotherapy also received postoperative systemic chemotherapy. Patient and tumor characteristics were examined in a multivariable logistic regression model. RESULTS: Between September 2005 and December 2010, 2,073 patients with stage II/III rectal cancer were enrolled in the database. Of these, 1,193 patients receiving neoadjuvant chemoradiotherapy were in the analysis, including 203 patients not receiving any adjuvant chemotherapy. For those seen by a medical oncologist, the most frequent reason chemotherapy was not recommended was comorbid illness (25 of 50, 50%); the most frequent reason chemotherapy was not received even though it was recommended or discussed was patient refusal (54 of 74, 73%). After controlling for NCCN Cancer Center and clinical TNM stage in a multivariable logistic model, factors significantly associated with not receiving adjuvant chemotherapy were age, Eastern Cooperative Oncology Group performance status ≥ 1, on Medicaid or indigent compared with private insurance, complete pathologic response, presence of re-operation/wound infection, and no closure of ileostomy/colostomy. CONCLUSION: Even at specialty cancer centers, a sizeable minority of patients with rectal cancer treated with curative-intent neoadjuvant chemoradiotherapy do not complete postoperative chemotherapy. Strategies to facilitate the ability to complete this third and final component of curative intent treatment are necessary.
Authors: Maria Pisu; Lisa C Richardson; Young-Il Kim; Helen Krontiras; Michelle Y Martin; Maribel Salas; Lori A Pollack Journal: J Natl Med Assoc Date: 2010-03 Impact factor: 1.798
Authors: Deirdre P Cronin; Linda C Harlan; Arnold L Potosky; Limin X Clegg; Jennifer L Stevens; Margaret M Mooney Journal: Am J Gastroenterol Date: 2006-10 Impact factor: 10.864
Authors: Arnold L Potosky; Linda C Harlan; Richard S Kaplan; Karen A Johnson; Charles F Lynch Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544
Authors: Dorothy Romanus; Martin R Weiser; John M Skibber; Anna Ter Veer; Joyce C Niland; John L Wilson; Ashwani Rajput; Yu-Ning Wong; Al B Benson; Stephen Shibata; Deborah Schrag Journal: J Natl Compr Canc Netw Date: 2009-09 Impact factor: 11.908
Authors: Madhu Muralee; Rajesh Singh; Arun Peter Mathew; Kurian Cherian; K Chandramohan; Paul Augustine; S Roshni; Iqbal Ahamed Journal: Indian J Surg Oncol Date: 2017-04-26
Authors: Deborah Schrag; Martin R Weiser; Karyn A Goodman; Mithat Gonen; Ellen Hollywood; Andrea Cercek; Diane L Reidy-Lagunes; Marc J Gollub; Jinru Shia; Jose G Guillem; Larissa K F Temple; Philip B Paty; Leonard B Saltz Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544